These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7140944)

  • 1. Biotransformation of epomediol. II - Urinary metabolites in the rat, dog and man.
    Ventura P; Pria R
    Farmaco Prat; 1982 Sep; 37(9):289-95. PubMed ID: 7140944
    [No Abstract]   [Full Text] [Related]  

  • 2. Capillary gas chromatographic determination of epomediol in human plasma and urine using a rapid solid-phase extraction.
    Girometta MA; Loschi L; Ventura P; Canali S; Giachetti C; Zanolo G
    Biomed Chromatogr; 1989 Sep; 3(5):199-202. PubMed ID: 2804425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation of epomediol. I--Isolation and identification of main metabolites in the rat.
    Ventura P; Selva A
    Biomed Mass Spectrom; 1982 Jan; 9(1):18-21. PubMed ID: 7059659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action of acute ethanol intake on rat biliary secretion: effect of epomediol.
    Chiarantini E; Mazzanti R; Buzzelli G; Chieca R; Coletta D; Orlandini F; Romeo D; Arena U
    Farmaco Prat; 1986 Sep; 41(9):307-12. PubMed ID: 3770160
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of epomediol on the recovery time of taurocholic acid captation in the perfused rat liver after suspension of the treatment with ethynylestradiol.
    Chiarantini E; Chieca R; Orlandini F; Romeo D; Buzzelli G; Gentilini P
    Farmaco Prat; 1986 Nov; 41(11):358-62. PubMed ID: 3803561
    [No Abstract]   [Full Text] [Related]  

  • 6. [Plasmatic clearance of antipyrine after treatment with epomediol].
    Del Vecchio S; Delle Monache M; Basoli A; Munoz ME; Alessandrini A; Ventura P; Schiavi M; Ricci GL
    Medicina (Firenze); 1988; 8(4):446-8. PubMed ID: 3244305
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of biliary epomediol-beta-glucuronide levels with bile flow enhancement in the rat.
    Ventura P; Lumachi B; Luzzani F; Scuri R
    Arzneimittelforschung; 1985; 35(10):1548-9. PubMed ID: 4074413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epomediol on bile flow and composition in normal rats and in rats with ethynylestradiol-induced cholestasis.
    Zuin M; Dioguardi ML; Festorazzi S; Podda M
    Farmaco Prat; 1981 Aug; 36(8):383-9. PubMed ID: 7274418
    [No Abstract]   [Full Text] [Related]  

  • 9. [Epomediol-induced modifications of the biohumoral picture in hepatic cirrhosis with or without cholestasis].
    Alberti A; Andreuzzi B; Santese R; Rotondo F
    Clin Ter; 1983 Feb; 104(3):227-33. PubMed ID: 6345051
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic effect of a new molecule, epomediol, in intrahepatic cholestasis].
    Pasetti GC; De Simoni M; Giuberti T; Pedretti G; Pelosi G
    Clin Ter; 1982 May; 101(4):371-86. PubMed ID: 7105642
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy and tolerance of intravenously administered epomediol in patients with hepatopathy].
    Fiocchi G; Dieci MG; Fiorani F; Galvani V; Lissandrin MR; Martino P; Politi E; Sotti A; Carrara GC
    Clin Ter; 1988 Oct; 127(1):37-41. PubMed ID: 2976340
    [No Abstract]   [Full Text] [Related]  

  • 12. [Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double-blind study].
    Pierri G; Giorgio A; Amoroso P; Fico P; Finelli L
    Clin Ter; 1985 Mar; 112(6):527-35. PubMed ID: 3893863
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotransformation of epomediol. III. Gas chromatographic analysis of rat plasma, bile, urine and faeces.
    Ventura P; Serafini S; Pria R
    J Chromatogr; 1982 Aug; 245(3):350-4. PubMed ID: 7130331
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of the terpenic compound epomediol on biliary secretion and bile composition in the rat.
    Zanninelli G; Tavanti A; Munoz ME; Ricci GL
    J Hepatol; 1992 Jan; 14(1):64-70. PubMed ID: 1737917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antilipemic activity of epomediol in patients with primary hyperlipidemia].
    Saba P; Galeone F; Natali A; Scalabrino A; Giuntoli F; Brunelleschi G
    Clin Ter; 1987 Jan; 120(1):37-43. PubMed ID: 2973855
    [No Abstract]   [Full Text] [Related]  

  • 16. Protective effect of epomediol on calcium release induced by palmitoyl CoA in the sarcoplasmic reticulum.
    Bindoli A; Cavallini L; Siliprandi N
    Pharmacol Res Commun; 1984 Jul; 16(7):647-52. PubMed ID: 6473484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the plasma clearance of antipyrine after treatment of healthy male volunteers with epomediol.
    Del Vecchio S; Ulissi A; Tavanti A; Delle Monache M; Munoz ME; Ventura P; Schiavi A; Ricci GL
    J Hepatol; 1990 Nov; 11(3):390-1. PubMed ID: 2290033
    [No Abstract]   [Full Text] [Related]  

  • 18. Activity of epomediol in the treatment of hepatopathies: a double-blind multi-centre study.
    Capurso L; Kock M; Ferrario F; Del Sette F; Gramolini C; Castiglioni CL
    J Int Med Res; 1987; 15(3):134-47. PubMed ID: 3301453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat.
    Cuevas MJ; Almar M; González-Gallego J
    Pharmacol Toxicol; 2002 Mar; 90(3):121-6. PubMed ID: 12071332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies of trans-sobrerol metabolism: rat, dog and human urine.
    Ventura P; Schiavi M; Serafini S; Selva A
    Xenobiotica; 1985 Apr; 15(4):317-25. PubMed ID: 4024666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.